Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug discovery stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Oct 29, 2026

University of Eastern Finland identifies vitamin transporter protein for brain drug delivery

Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.

Oct 29, 2026·4 sources
00

Flagship Pioneering merges Etiome, Cellarity and Empress Therapeutics into Etcelera

Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.

Oct 29, 2026·2 sources
00

International study identifies 127 genetic risk regions for Alzheimer's disease

A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.

Oct 29, 2026·3 sources
00
Oct 22, 2026

Molecular glue RPT04402 stabilizes PP2A protein to inhibit lung and uterine cancer development

Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.

Oct 22, 2026·3 sources
00
Oct 20, 2026

OpenAI acquires Orchestra Bio to expand into pharmaceutical AI

OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development. The acquisition signals OpenAI's expansion into the healthcare sector, following rival Anthropic's similar moves.

Oct 20, 2026·3 sources
00
Oct 15, 2026

AstraZeneca partners with insitro on $1.86 billion AI drug discovery deal

AstraZeneca signed a collaboration with machine learning biotech insitro worth up to $1.86 billion to discover new medicines for liver and heart diseases using AI-driven drug discovery platforms.

Oct 15, 2026·3 sources
00
Sep 24, 2026

Roche signs drug discovery deal with Atavistik Bio worth up to $2 billion

Swiss drugmaker Roche has entered a partnership with Atavistik Bio potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. The deal includes $70 million upfront with an additional $1.9 billion in potential milestone payments.

Sep 24, 2026·6 sources
00
Sep 17, 2026

Roche, Dualitas partner on $1B bispecific antibody discovery deal

Roche will collaborate with Dualitas to screen over 300,000 bispecific antibody combinations for inflammatory and immunology conditions in a deal worth up to $1 billion.

Sep 17, 2026·2 sources
00
Sep 7, 2026

AI-designed drug shows promise in reversing biological aging markers in clinical trial

Insilico Medicine announced that rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reduce biological age markers in a 42-patient trial. Six independently built aging clocks all showed patients on the drug appeared biologically younger, according to a study conducted with researchers from Harvard Medical School, Stanford University, and The Broad Institute.

Sep 7, 2026·4 sources
00

AI-discovered drug shows promise in reversing biological aging markers

Rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reverse biological signs of aging in a study, according to its developer, suggesting broader potential applications beyond its original target condition.

Sep 7, 2026·2 sources
00
Aug 22, 2026

Outer Biosciences emerges from stealth with AI platform that keeps human skin alive for weeks

Michael Polansky's biotech startup Outer Biosciences has emerged from stealth after four years, revealing technology that keeps surgically discarded human skin tissue alive for up to a month outside the body. The company trains AI models on how the living tissue reacts to compounds to discover new skincare treatments.

Aug 22, 2026·4 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Aug 6, 2026

AI and Genetics Research Identifies New Drug Targets and Candidates for Osteoarthritis Treatment

Researchers at the University of Utah Health have used artificial intelligence and genetic analysis to identify molecular signals and drug candidates that could modify osteoarthritis disease progression, moving beyond current symptom-management approaches. The research includes insights into purinergic signaling pathways that influence joint inflammation and cartilage degeneration.

Aug 6, 2026·4 sources
00
May 9, 2026

Google's Isomorphic Labs Raises Over $2 Billion for AI Drug Discovery

Isomorphic Labs, the AI-powered drug discovery company spun out of Google DeepMind, is in advanced discussions to raise more than $2 billion in new funding, marking one of the largest biotech AI rounds to date.

May 9, 2026·1 source
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Subtopics

AI for developers4Drug development4Longevity biotech founders4AI in healthcare3AI research & benchmarks3Biotech startup3Pharma3AI applications2AI drug discovery2Alzheimer’s & dementia2Alzheimer's disease2Biomarkers & bloodwork testing2Biomedical research2Biotechnology2Drug Approval and Clinical Trials2Drug Policy, Pricing & Approval2Longevity & aging2Medical research2Mergers & acquisitions (M&A)2Neurodegenerative disease2Venture capital funding2AI1AI agents1AI data analysis1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories